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Randomized controlled trials can provide optimal clinical ev-
idence to assess the benefits of new devices, and it is these 
data that often shape device usage in real-world practice. 
However, individual clinical trial results sometimes appear 
discordant for the same device, and alternative devices are 
sometimes not employed in similar patient populations. To 
make sound evidence-based decisions, clinicians routinely 
rely on cross-trial comparisons from different trials of sim-
ilar but not identical patient populations to assess competing 
technology when head-to-head randomized comparisons are 
unavailable. ASAIO Journal 2019; 65:293–296.
Key Words: left ventricular assist device, advanced heart 
failure, stroke
Randomized clinical trials provide the best means to com-
pare devices; however, there are no such trials with current left 
ventricular assist device (LVAD) technology. Comparing results 
across trials of LVADs becomes problematic owing to differ-
ences in trial inclusion and exclusion criteria, the evolution of 
trial design from discrete bridge to transplant (BTT) and desti-
nation therapy (DT) trials to a combined indication, evolving 
definitions of adverse events, and evolution of surgical and 
medical management over time. An improved understanding 
of the morbidity related to LVAD technology has resulted in 
increasing specificity of definitions, sometimes resulting in 
overly conservative definitions in the older trials when com-
pared with newer trials.
Another limitation when comparing nonrandomized clinical 
trials involves potential differences in the methodology in the 
reporting of events. Evolving clinical trial designs have led to 
mixed populations with varying success criteria, which limit 
the use of the traditional incidence, or risk of an event over 
an entire population, as a reliable expression of adverse event 
probability. For example, HeartWare Left Ventricular Assist De-
vice System (HVAD) BTT clinical trials reported neurologic 
event rates,1–3 while the MOMENTUM 3 clinical trial reported 
cumulative incidence (frequency) of neurologic events.4,5 
In the MOMENTUM 3 trial, 40 of 189 HeartMate 3 (HM3) 
patients were transplanted before 2 years, with some as early 
as the first 30 days.5 Despite this, all 40 patients were included 
in the denominator as “at risk” for stroke at 2 years. This leads 
to an error in actual patients “at risk” and has the potential 
effect of artificially lowering the incidence of adverse events. 
Thus, direct cross-trial comparisons of neurologic events are 
not possible.
Given the lack of randomized trials and differences in the 
existing mechanical circulatory support trials, we undertook a 
novel approach to the comparison of LVAD trials via the gener-
ation of a “hybrid” intention to treat population, using existing 
clinical trial datasets. While such an approach is not a substi-
tute for a randomized comparison, this analysis highlights the 
need for a more rigorous examination of clinical trial designs 
and data analyses.
To generate a “HYBRID-HVAD” population that would be 
comparable with the HeartMate 3 cohort of the MOMENTUM 
3 trial, a mix of DT:BTT patients was needed.5 Thus, patients 
receiving an HVAD system from the DT ENDURANCE Sup-
plemental7 and the continued access protocol (CAP) cohort 
of the ADVANCE BTT+CAP trials were combined to form the 
HYBRID-HVAD population for this analysis. Because the MO-
MENTUM 3 trial design specifically excluded all patients with 
fulminant cardiogenic shock,8 these patients were removed 
from the HYBRID-HVAD population.
Of the 550 patients in the combined ADVANCE+CAP and 
ENDURANCE SUPPLEMENTAL cohorts, 14 of 242 patients in 
the CAP dataset and 12 of 308 patients in the SUPPLEMENTAL 
dataset were excluded due to presence of cardiogenic shock 
at baseline (Figure 1). The final combined HYBRID-HVAD 
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population included 228 ADVANCE+CAP and 296 ENDUR-
ANCE SUPPLEMENTAL patients for a total of 524 patients. 
Apart from more HYBRID-HVAD patients having ischemic car-
diomyopathy, the HYBRID-HVAD cohort was clinically similar 
to HM3 patients in the MOMENTUM 3 clinical trial (Table 1). 
Importantly, the overall BTT:DT ratio was very similar, with 
56.5% DT and 43.5% BTT, compared with 58% long-term 
(DT) and 42% short-term (BTT) patients in MOMENTUM 3.5 
The proportion of patients transplanted within 2 years in the 
HYBRID-HVAD BTT cohort was 50.4% compared with 50% 
of BTT HM3 patients in MOMENTUM 3.5
The HVAD and MOMENTUM 3 trials used differing adverse 
event definitions. HVAD clinical trials used the neurologic 
event definitions from Interagency Registry of Mechanically 
Assisted Circulatory Support (INTERMACS) protocol 3.01,2,7 
while MOMENTUM 3 applied the neurologic definitions 
used in INTERMACS protocol 5.4,5,8 These protocols were sig-
nificantly different in the adjudication of what qualified as a 
stroke event. For example, a subdural hematoma after a fall 
was adjudicated as a stroke in the HVAD trials per the defini-
tions in protocol 3.0,9 whereas these were appropriately clas-
sified as an “other neurologic event” in the MOMENTUM trial 
using the new INTERMACS adverse event protocols.4 To allow 
for a comparison of neurologic outcomes, the incidence of 
total neurologic events was compared. The “neurologic dys-
function” category included strokes (both ischemic and hem-
orrhagic events), transient ischemic attacks (TIAs), and other 
nonstroke events such as confusion, seizure, and encepha-
lopathy; therefore, total neurologic events should be broadly 
and equally captured between trials. We found no signifi-
cant difference in the incidence of overall neurologic events 
occurring at either 6 months or 2 years in the HYBRID-HVAD 
population (14.1% and 23.3%, respectively) relative to the 
MOMENTUM 3 HM3 population (13.9% and 21.7%, respec-
tively) (Figure 2A).
This analysis might be criticized for a lack of discussion of 
the most severe of the neurologic events, disabling strokes. 
However, the ADVANCE BTT+CAP study was performed be-
fore understanding the need for analysis of mRS scores and 
stroke recovery. However, the freedom from disabling strokes 
(mRS>3) in the ENDURANCE Supplemental trial was presented 
by Teuteberg et al.4 at the 2018 ISHLT Congress in Nice, France. 
Despite the fact that the ENDURANCE Supplemental trial used 
a definition that pulled in more “other neurologic events” into 
the stroke category (e.g. an “other neurologic event” patient 
who died in the MOMENTUM 3 short-term cohort due to a 
subdural hematoma after a fall4 was not counted as a disabling 
stroke, but would have been in ENDURANCE Supplemental), 
and the excess by more than 10% of ischemic patients and 
inclusion of cardiogenic shock patients in the pure DT popula-
tion in the HVAD trial,4 we find similar results when compared 
with MOMENTUM 3 (Figure 2B). The MOMENTUM 3 trial re-
ported a 2-year freedom from disabling strokes of 92.5% in the 
HM3 cohort,5 compared with 90.7% in the HVAD cohort of 
ENDURANCE Supplemental.10
The goal of these comparisons is to assist the shared deci-
sion-making process in the absence of head-to-head clinical 
trial comparisons. In this analysis, with a focus on neuro-
logic events as an example of difficulties encountered when 
Figure 1. Generation of the hybrid long-term HVAD population.  
Table 1.  Baseline Characteristics of the HVAD-HYBRID 
Population
Baseline Characteristics
HYBRID-HVAD, 
N = 524
MOMENTUM 37
HM3, N = 190
Age (years) 59.0 ± 12.9 61 ± 12
Female gender (%) 22.9 21.1
Race (% white) 69.7 66.8
Body surface area (m2) 2.0 ± 0.28 2.1 ± 0.3
INTERMACS profile (%)   
  1 0.0 0.5
  2 37.2 32.1
  3 43.6 53.2
  4–7 19.3 14.2
Ischemic etiology of heart 
failure, %
47.3 42.1
Left ventricular ejection  
fraction (%)
17.2 ± 6.1 17.2 ± 4.9
Creatinine (µmol/L) 1.4 ± 0.5 1.4 ± 0.4
Prior cardiac surgery, % 29.4 31.7
Cardiac index (L/min/m2) 2.2 ± 0.6 2.0 ± 0.5
Mean arterial blood pressure 
(mm Hg)
78.3 ± 10.6  
(N = 355)
79.5 ± 10.1
Pulmonary capillary wedge 
pressure (mm Hg)
22.2 ± 8.4  
(N = 272)
23.9 ± 8.6
Implant strategy, %   
  Bridge to transplant 43.5 42
  Destination therapy 56.5 58
Values presented as a ± b represent the mean value  ±  the stand-
ard deviation.
HVAD indicates HeartWare Ventricular Assist Device; HM3, 
HeartMate 3; INTERMACS, Interagency Registry of Mechanically 
Assisted Circulatory Support.
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comparing outcomes across trials of contemporary LVADs. 
Considerations of the manner in which event rates are deter-
mined can also limit comparisons. In the MOMENTUM 3 trial, 
40 of 189 HM3 patients were transplanted before 2 years, with 
some as early as the first 30 days.5 Despite this, all 40 patients 
were included in the denominator as “at risk” for stroke at 2 
years. This leads to an error in actual patients “at risk” and 
has the potential effect of artificially lowering the incidence 
of adverse events and severely limiting the appropriateness of 
cross-trial comparisons. The HM3 device was also evaluated 
in a Conformité Européene (CE) Mark trial, which also used 
the short-term/long-term design of MOMENTUM 3 but with 
a single HM3 study arm. The results of the long-term cohort 
of patients supported for 2 years was recently published.6 In 
that trial, 24% of patients were reported to have experienced a 
stroke through 2 years of support. The difference in the stroke 
rate reported in the CE Mark trial at 24% and the low 10% 
rate reported in MOMENTUM 3 can be partly attributed to the 
fact that they also reported a very low transplant rate of 10%, 
less than half that of the MOMENTUM 3 trial. Therefore, more 
patients in the denominator in that trial were actually on sup-
port and at risk of having a stroke, which lends to it likely being 
a more reliable report of stroke incidence with the HM3.
There are some inherent limitations to this analysis. The AD-
VANCE CAP and ENDURANCE Supplemental trials were not 
performed contemporaneously with the MOMENTUM 3 trial. 
Also, the sample size of the HM3 population was quite small 
compared with the HYBRID HVAD population. Also, HM3 
outcomes in MOMENTUM 3 appear discordant with those 
observed in similar trials in Europe for CE Mark;11 therefore, 
more experience with the HM3 system could result in more 
refined outcomes not evident in a smaller population. The 
MOMENTUM 3 trial includes a large CAP experience which 
may address the concerns of limited experience in the future.9 
Uncaptured differences in patient selection and patient man-
agement arising from knowledge gained between clinical trials 
Figure 2. A: Incidence of total neurologic events in the HYBRID HVAD group compared with the MOMENTUM 3 HeartMate 3 (HM3) 
group.6,7 There were 413/524 of HVAD patients and 130/151 HM3 patients on support at the time of the 6-month analysis, and 224/524 of 
HVAD patients and 117/189 HM3 patients on support at the time of the 2-year analysis. B: Comparison of freedom from disabling stroke 
rates in MOMENTUM 3 and ENDURANCE Supplemental. The freedom from disabling strokes (strokes with a modified Rankin Score (mRS) 
> 3) in the HM3 and HM2 cohorts of the MOMENTUM Trial compared with the freedom from disabling strokes in the ENDURANCE Supple-
mental Trial. (HM3 and HM2 curves reprinted with permission from Mehra, et al.5 Copyright ©2018 Massachusetts Medical Society.) 
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may have led to unmeasured differences that could impact the 
incidence of neurologic events.
In summary, there is an urgent need in the medical commu-
nity to make evidenced-based and informed decisions when it 
comes to device selection. However, until head-to-head ran-
domized studies of contemporary devices are available, clini-
cians must resort to cross-trial comparisons, frequently from 
significantly discordant trials. In our analysis, neurologic event 
rates appear to be equivalent between the HVAD, HM3 and 
HMII, particularly fatal and disabling strokes. We have outlined 
a careful examination of the trial design, patient populations, 
and statistical analyses required to minimize biased conclu-
sions. Future studies with uniform event definitions, careful 
consideration of statistical designs and analyses are required to 
further elucidate comparative contemporary device outcomes.
ACKNOWLEDGMENT
The authors gratefully acknowledge the thoughtful discussions and 
insights contributed by Thomas Vassiliades of Medtronic, as well as the 
statistical programming support of Jie Qin and Wei Xu, also of Medtronic.
REFERENCES
 1. Aaronson KD, Slaughter MS, Miller LW, et al; HeartWare 
Ventricular Assist Device (HVAD) Bridge to Transplant 
ADVANCE Trial Investigators: Use of an intrapericardial, con-
tinuous-flow, centrifugal pump in patients awaiting heart trans-
plantation. Circulation 125: 3191–3200, 2012.
 2. Slaughter MS, Pagani FD, McGee EC, et al; HeartWare Bridge to 
Transplant ADVANCE Trial Investigators: HeartWare ventricular 
assist system for bridge to transplant: combined results of the 
bridge to transplant and continued access protocol trial. J Heart 
Lung Transplant 32: 675–683, 2013.
 3. Aaronson KD, Silvestry SC, Maltais S, et al: Patients awaiting heart 
transplantation on HVAD support for greater than 2 years. 
ASAIO J 62: 384–389, 2016.
 4. Mehra MR, Naka Y, Uriel N, et al; MOMENTUM 3 Investigators: 
A fully magnetically levitated circulatory pump for advanced 
heart failure. N Engl J Med 376: 440–450, 2017.
 5. Mehra MR, Goldstein DJ, Uriel N, et al; MOMENTUM 3 
Investigators: Two-year outcomes with a magnetically levitated 
cardiac pump in heart failure. N Engl J Med 378: 1386–1395, 
2018.
 6. Scmitto JD, Pya Y, Zimpfer D, et al: Long-term evaluation of a fully 
magnetically levitated circulatory support device for advanced 
heart failure-two-year results from the HeartMate 3 CE Mark 
Study. Eur J Heart Fail 2018. doi: 10.1002/ejhf.1284. [Epub 
ahead of print]
 7. Milano CA, Rogers JG, Tatooles AJ, et al; ENDURANCE 
Investigators: HVAD: The ENDURANCE supplemental trial. 
JACC Heart Fail 6: 792–802, 2018.
 8. Heatley G, Sood P, Goldstein D, et al; MOMENTUM 3 Investigators: 
Clinical trial design and rationale of the multicenter study of 
maglev technology in patients undergoing mechanical circula-
tory support therapy with heartmate 3 (MOMENTUM 3) investi-
gational device exemption clinical study protocol. J Heart Lung 
Transplant 35: 528–536, 2016.
 9. Teuteberg JJ, Stewart GC, Jessup M, et al: Implant strategies change 
over time and impact outcomes: Insights from the INTERMACS 
(Interagency Registry for Mechanically Assisted Circulatory 
Support). JACC Heart Fail 1: 369–378, 2013.
 10. Teuteberg JJ, Rogers JG, Milano CA, et al: Blood pressure manage-
ment ameliorates neurological events. J Heart Lung Transplant 
37:S11, 2018.
 11. Krabatsch T, Netuka I, Schmitto JD, et al: Heartmate 3 fully mag-
netically levitated left ventricular assist device for the treatment 
of advanced heart failure -1 year results from the Ce mark trial. 
J Cardiothorac Surg 12: 23, 2017.
